Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

NCT ID: NCT00661713

Last Updated: 2019-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1631 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-06-30
• Study Completion Date: 2010-12-31

Brief Summary

The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccination schedule in an adolescent population.

Conditions

Meningococcal Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

rMenB06

Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB0

Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB016

Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB01

Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB026

Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB02

Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB012

Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

rMenB6

Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).

Group Type: EXPERIMENTAL

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

Interventions

rMenB+OMV NZ

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: BIOLOGICAL

Other Intervention Names

Serogroup B Meningococcal Vaccine

Eligibility Criteria

Inclusion Criteria

1)11-17 years of age inclusive who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment;

2)who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period);

3)in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria

1. History of any meningococcal B vaccine administration;

2. Current or previous, confirmed or suspected disease caused by N. meningitidis;

3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;

4. Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥38°C) within the previous day;

5. Antibiotics within 6 days prior to enrollment;

6. Pregnancy or nursing (breastfeeding) mothers;

7. Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the 7 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry;

8. Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).

9. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, including use of corticosteroids in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. [Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body is allowed]; immunostimulants;

10. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;

11. History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;

12. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior (60 days for live viral vaccines) and throughout the study period (exception: licensed fluvaccine should not be administered within 14 days prior to enrollment; routine vaccine administration may be administered after the blood draw at Study Month 7);

13. Participation in another clinical trial within the last 90 days or planned for during study;

14. Family members and household members of research staff;

15. Any condition which in the opinion of the investigator and/or the Regional MD may interfere with the evaluation of the study objectives.

• Minimum Eligible Age: 11 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Novartis Vaccines

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Vaccines

Role: STUDY_CHAIR

Novartis Vaccines

Locations

Site 13: Liceo Diego Aracena de Lo Barnechea

Monseñor Escrivá de Balaguer 14630, Lo Barnechea, Santiago Metropolitan, Chile

Site 41: Colegio Antonio Hermida Fabres

Av. Coronel Alejandro Sepúlveda N° 6801, , Chile

Site 43: Liceo José Victorino Lastarria

Av. Miguel Claro N° 32, , Chile

Site 51: Centro Para vacunas en Desarrollo. Hospital de Niños Roberto del Rio

Av. Prof Zañartu 1085, , Chile

Site 15: Liceo Carmela Carvajal de Prat

Avda. Italia 980, , Chile

Site 14: Colegio Parroquial Santa Rosa de Lo Barnechea

Avda. Raúl Labbé Nº 13.799, , Chile

Site 42: Centro Educacional Eduardo de la Barra

Calle A, N° 6301, , Chile

Site 61: Facultad de Medicina. Universidad de Valparaíso.

Hontaneda # 2653. Valparaíso, , Chile

Site 11: Complejo Educacional Eduardo Cuevas Valdés

Lo Barnechea, , Chile

Site 12: Colegio San Jose de Lo Barnechea

Santiago, , Chile

Countries

Chile

References

Bartolini E, Borgogni E, Bruttini M, Muzzi A, Giuliani M, Iozzi S, Petracca R, Martinelli M, Bonacci S, Marchi S, Brettoni C, Donati C, Torricelli G, Guidotti S, Domina M, Beninati C, Teti G, Felici F, Rappuoli R, Castellino F, Del Giudice G, Masignani V, Pizza M, Maione D. Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. Nat Commun. 2020 Oct 5;11(1):4994. doi: 10.1038/s41467-020-18791-0.

Reference Type: DERIVED

PMID: 33020485 (View on PubMed)

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18.

Reference Type: DERIVED

PMID: 22260988 (View on PubMed)

Other Identifiers

V72P10

Identifier Type: -

Identifier Source: org_study_id